Novavax Q2 FY26 turns to net loss of $53.39 million; revenue drops 76.29% to $56.7 million

Reuters2026/08/06 11:54

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Novavax swung to a net loss of USD 53.39 million, or USD 0.32 a share, in the quarter ended June 30, 2026.
Revenue fell 76.29% to USD 56.7 million, led by licensing, royalties and other dropping 83.45% to USD 37.84 million.
Product sales rose 75.78% to USD 18.85 million, driven by higher supply sales as Nuvaxovid sales fell to no revenue.
Sanofi confirmed advanced regulator talks on Phase 3 timing for its COVID-19/flu combination vaccine, triggering a USD 125 million milestone on trial start.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001000694-26-000018), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Novavax Q2 FY26 turns to net loss of $53.39 million; revenue drops 76.29% to $56.7 million

You may also like

Crypto prices